Abstract
Adoptive cellular therapy (ACT) with various lymphocytes or antigen-presenting cells is one stone in the pillar of cancer immunotherapy, which relies on the tumor-specific T cell. The transfusion of bulk T-cell population into patients is an effective treatment for regression of cancer. In this chapter, we summarize the development of various strategies in ACT for cancer immunotherapy and discuss some of the latest progress and obstacles in technical, safety, and even regulatory aspects to translate these technologies to the clinic. ACT is becoming a potentially powerful approach to cancer treatment. Further experiments and clinical trials are needed to optimize this strategy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmadi, M., King, J. W., et al. (2011). CD3 limits the efficacy of TCR gene therapy in vivo. Blood, 118(13), 3528–3537.
Ahmadzadeh, M., Johnson, L. A., et al. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood, 114(8), 1537–1544.
Airoldi, I., Bertaina, A., et al. (2015). gammadelta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alphabeta+/CD19+ lymphocytes. Blood, 125(15), 2349–2358.
Alexander, S., & Friedl, P. (2012). Cancer invasion and resistance: Interconnected processes of disease progression and therapy failure. Trends in Molecular Medicine, 18(1), 13–26.
Altvater, B., Landmeier, S., et al. (2009). 2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clinical Cancer Research, 15(15), 4857–4866.
Amir, A. L., van der Steen, D. M., et al. (2011). PRAME-specific allo-HLA–restricted T cells with potent antitumor reactivity useful for therapeutic T-cell receptor gene transfer. Clinical Cancer Research, 17(17), 5615–5625.
Amsen, D., Blander, J. M., et al. (2004). Instruction of distinct CD4 T helper cell fates by different notch ligands on antigen-presenting cells. Cell, 117(4), 515–526.
Andersen, R. S., Thrue, C. A., et al. (2012). Dissection of T-cell antigen specificity in human melanoma. Cancer Research, 72(7), 1642–1650.
Apetoh, L., Ghiringhelli, F., et al. (2007). Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine, 13(9), 1050–1059.
Arai, S., Meagher, R., et al. (2008). Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: A phase I trial. Cytotherapy, 10(6), 625–632.
Araki, R., Uda, M., et al. (2013). Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature, 494(7435), 100–104.
Atkins, M. B., Gould, J. A., et al. (1986). Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. Journal of Clinical Oncology, 4(9), 1380–1391.
Atkins, M. B., Kunkel, L., et al. (2000). High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. The Cancer Journal from Scientific American, 6(Suppl 1), S11–S14.
Attig, S., Hennenlotter, J., et al. (2009). Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Research, 69(21), 8412–8419.
Awwad, M., & North, R. J. (1988). Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology, 65(1), 87–92.
Baker, J., Verneris, M. R., et al. (2001). Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood, 97(10), 2923–2931.
Bansal, R. R., Mackay, C. R., et al. (2012). IL-21 enhances the potential of human gammadelta T cells to provide B-cell help. European Journal of Immunology, 42(1), 110–119.
Bendle, G. M., Linnemann, C., et al. (2010). Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature Medicine, 16(5), 565–570. 561p following 570.
Benson, D. M., Jr., Bakan, C. E., et al. (2010). The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: A therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody. Blood, 116(13), 2286–2294.
Berdeja, J. G., Hess, A., et al. (2007). Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab. Clinical Cancer Research, 13(8), 2392–2399.
Besser, M. J., Shapira-Frommer, R., et al. (2009). Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients. Journal of Immunotherapy, 32(4), 415–423.
Besser, M. J., Shapira-Frommer, R., et al. (2010). Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clinical Cancer Research, 16(9), 2646–2655.
Besser, M. J., Shapira-Frommer, R., et al. (2013). Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clinical Cancer Research, 19(17), 4792–4800.
Bindea, G., Mlecnik, B., et al. (2014). The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology, 3(1), e27456.
Blankenstein, T., Leisegang, M., et al. (2015). Targeting cancer-specific mutations by T cell receptor gene therapy. Current Opinion in Immunology, 33, 112–119.
Bock, A. M., Knorr, D., et al. (2013). Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs). Journal of Visualized Experiments, 74, e50337.
Boissel, L., Betancur, M., et al. (2009). Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells. Leukemia Research, 33(9), 1255–1259.
Boissel, L., Betancur, M., et al. (2012). Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens. Leukemia and Lymphoma, 53(5), 958–965.
Boissel, L., Betancur-Boissel, M., et al. (2013). Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. Oncoimmunology, 2(10), e26527.
Boldt, D. H., Mills, B. J., et al. (1988). Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Research, 48(15), 4409–4416.
Bollard, C. M., Gottschalk, S., et al. (2014). Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. Journal of Clinical Oncology, 32(8), 798–808.
Brahmer, J. R., Tykodi, S. S., et al. (2012). Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine, 366(26), 2455–2465.
Brentjens, R. J., Santos, E., et al. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clinical Cancer Research, 13(18 Pt 1), 5426–5435.
Brentjens, R. J., Riviere, I., et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood, 118(18), 4817–4828.
Bridgeman, J. S., Hawkins, R. E., et al. (2010). Building better chimeric antigen receptors for adoptive T cell therapy. Current Gene Therapy, 10(2), 77–90.
Brinkmann, O. A., Bruns, F., et al. (1999). Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). Anticancer Research, 19(2C), 1583–1587.
Burns, L. J., Weisdorf, D. J., et al. (2003). IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. Bone Marrow Transplantation, 32(2), 177–186.
Butler, M. O., Friedlander, P., et al. (2011). Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Science Translational Medicine, 3, 80ra34.
Caccamo, N., Todaro, M., et al. (2012). IL-21 regulates the differentiation of a human gammadelta T cell subset equipped with B cell helper activity. PLoS One, 7(7), e41940.
Cameron, B. J., Gerry, A. B., et al. (2013). Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Science Translational Medicine, 5(197), 197ra103.
Capobianco, A., Rovere-Querini, P., et al. (2006). Melanoma cells interfere with the interaction of dendritic cells with NK/LAK cells. International Journal of Cancer, 119(12), 2861–2869.
Carpenito, C., Milone, M. C., et al. (2009a). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences, 106(9), 3360–3365.
Carpenito, C., Milone, M. C., et al. (2009b). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proceedings of the National Academy of Sciences of the United States of America, 106(9), 3360–3365.
Carreno, B. M., Magrini, V., et al. (2015). Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science, 348(6236), 803–808.
Cecco, S., Muraro, E., et al. (2011). Cancer vaccines in phase II/III clinical trials: State of the art and future perspectives. Current Cancer Drug Targets, 11(1), 85–102.
Chambers, J. D., & Neumann, P. J. (2011). Listening to provenge – What a costly cancer treatment says about future medicare policy. New England Journal of Medicine, 364(18), 1687–1689.
Chen, L., & Flies, D. B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews Immunology, 13(4), 227–242.
Chhabra, A. (2011). TCR-engineered, customized, antitumor T cells for cancer immunotherapy: Advantages and limitations. ScientificWorldJournal, 11, 121–129.
Chi, K. H., Liu, S. J., et al. (2005). Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. Journal of Immunotherapy, 28(2), 129–135.
Chia, W. K., Teo, M., et al. (2014). Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Molecular Therapy, 22(1), 132–139.
Chmielewski, M., & Abken, H. (2012). CAR T cells transform to trucks: Chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunology, Immunotherapy, 61(8), 1269–1277.
Chmielewski, M., & Abken, H. (2015). TRUCKs: The fourth generation of CARs. Expert Opinion on Biological Therapy, 15(8), 1145–1154.
Chmielewski, M., Hombach, A. A., et al. (2014). Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunology Reviews, 257(1), 83–90.
Chometon, G., & Jendrossek, V. (2009). Targeting the tumour stroma to increase efficacy of chemo-and radiotherapy. Clinical and Translational Oncology, 11(2), 75–81.
Chu, J., Deng, Y., et al. (2014). CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia, 28(4), 917–927.
Clay, T. M., Custer, M. C., et al. (1999). Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. The Journal of Immunology, 163(1), 507–513.
Coffelt, S. B., Kersten, K., et al. (2015). IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature, 522(7556), 345–348.
Cohen, C. J., Zheng, Z., et al. (2005). Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. Journal of Immunology, 175(9), 5799–5808.
Cohen, C. J., Zhao, Y., et al. (2006). Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability. Cancer Research, 66(17), 8878–8886.
Cohen, C. J., Li, Y. F., et al. (2007). Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Research, 67(8), 3898–3903.
Cordova, A., Toia, F., et al. (2012). Characterization of human gammadelta T lymphocytes infiltrating primary malignant melanomas. PLoS One, 7(11), e49878.
Correia, D. V., Fogli, M., et al. (2011). Differentiation of human peripheral blood Vdelta1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood, 118(4), 992–1001.
Corrigan-Curay, J., Kiem, H. P., et al. (2014). T-cell immunotherapy: Looking forward. Molecular Therapy, 22(9), 1564–1574.
Couper, K. N., Lanthier, P. A., et al. (2009). Anti-CD25 antibody-mediated depletion of effector T cell populations enhances susceptibility of mice to acute but not chronic Toxoplasma gondii infection. Journal of Immunology, 182(7), 3985–3994.
Crompton, J. G., Sukumar, M., et al. (2015). Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Research, 75(2), 296–305.
Curran, M. A., Kim, M., et al. (2011). Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One, 6(4), e19499.
Curti, A., Ruggeri, L., et al. (2011). Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood, 118(12), 3273–3279.
Dao, T., Yan, S., et al. (2013). Targeting the intracellular WT1 oncogene product with a therapeutic human antibody. Science Translational Medicine, 5(176), 176ra133–176ra133.
Darcy, P. K., Neeson, P., et al. (2014). Manipulating immune cells for adoptive immunotherapy of cancer. Current Opinion in Immunology, 27, 46–52.
de la Cruz-Merino, L., Illescas-Vacas, A., et al. (2014). Radiation for awakening the dormant immune system, a promising challenge to be explored. Frontiers in Immunology, 5, 102.
DembiĆ, Z., Haas, W., et al. (1985). Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature, 320(6059), 232–238.
Dembic, Z., Haas, W., et al. (1986). Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature, 320(6059), 232–238.
Derre, L., Bruyninx, M., et al. (2007). In vivo persistence of codominant human CD8+ T cell clonotypes is not limited by replicative senescence or functional alteration. Journal of Immunology, 179(4), 2368–2379.
Di Mitri, D., Toso, A., et al. (2015). Molecular pathways: Targeting tumor-infiltrating myeloid-derived suppressor cells for cancer therapy. Clinical Cancer Research, 21(14), 3108–3112.
Dieli, F., Vermijlen, D., et al. (2007). Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Research, 67(15), 7450–7457.
Dillman, R. O., Duma, C. M., et al. (2004). Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. Journal of Immunotherapy, 27(5), 398–404.
Dillman, R. O., Duma, C. M., et al. (2009). Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. Journal of Immunotherapy, 32(9), 914–919.
Ding, Z. C., Lu, X., et al. (2014). Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Research, 74(13), 3441–3453.
Dudley, M. E., Wunderlich, J. R., et al. (2002a). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298(5594), 850–854.
Dudley, M. E., Wunderlich, J. R., et al. (2002b). A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. Journal of Immunotherapy, 25(3), 243–251.
Dudley, M. E., Wunderlich, J. R., et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. Journal of Clinical Oncology, 23(10), 2346–2357.
Dudley, M. E., Yang, J. C., et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. Journal of Clinical Oncology, 26(32), 5233–5239.
Dudley, M. E., Gross, C. A., et al. (2010). CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clinical Cancer Research, 16(24), 6122–6131.
Dudley, M. E., Gross, C. A., et al. (2013). Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. Journal of Clinical Oncology, 31(17), 2152–2159.
Dunn, G. P., Old, L. J., et al. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21(2), 137–148.
Duong, C. P., Yong, C. S., et al. (2015). Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Molecular Immunology, 67(2 Pt A), 46–57.
Eguizabal, C., Zenarruzabeitia, O., et al. (2014). Natural killer cells for cancer immunotherapy: Pluripotent stem cells-derived NK cells as an immunotherapeutic perspective. Frontiers in Immunology, 5, 439.
Ellebaek, E., Iversen, T. Z., et al. (2012). Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. Journal of Translational Medicine, 10, 169.
Errico, A. (2015). Genetics: Clonal and subclonal events in cancer evolution – Optimizing cancer therapy. Nature Reviews Clinical Oncology, 12(7), 372.
Esser, R., Muller, T., et al. (2012). NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. Journal of Cellular and Molecular Medicine, 16(3), 569–581.
Finke, S., Trojaneck, B., et al. (1998). Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Therapy, 5(1), 31–39.
Finney, H. M., Lawson, A. D., et al. (1998). Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. Journal of Immunology, 161(6), 2791–2797.
Finney, H. M., Akbar, A. N., et al. (2004). Activation of resting human primary T cells with chimeric receptors: Costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCRζ chain. The Journal of Immunology, 172(1), 104–113.
Fisher, R. I., Rosenberg, S. A., et al. (2000). Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. The Cancer Journal from Scientific American, 6(Suppl 1), S55–S57.
Flanigan, R. C., Mickisch, G., et al. (2004). Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis. Journal of Urology, 171(3), 1071–1076.
Fourcade, J., Sun, Z., et al. (2010). Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. Journal of Experimental Medicine, 207(10), 2175–2186.
Frantz, S. (2011). Engineered T-cell therapy shows efficacy in blood cancer. Nature Biotechnology, 29(10), 853–855.
Friedman, R. S., Spies, A. G., et al. (2004). Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. European Journal of Immunology, 34(4), 1091–1101.
Galluzzi, L., Vacchelli, E., et al. (2014). Classification of current anticancer immunotherapies. Oncotarget, 5(24), 12472–12508.
Gasser, S., Orsulic, S., et al. (2005). The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature, 436(7054), 1186–1190.
Gattinoni, L., Finkelstein, S. E., et al. (2005). Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. The Journal of Experimental Medicine, 202(7), 907–912.
Geller, M. A., & Miller, J. S. (2011). Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, 3(12), 1445–1459.
Geller, M. A., Cooley, S., et al. (2011). A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy, 13(1), 98–107.
Ghiringhelli, F., Menard, C., et al. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunology, Immunotherapy, 56(5), 641–648.
Gooden, M. J., de Bock, G. H., et al. (2011). The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. British Journal of Cancer, 105(1), 93–103.
Gorelik, L., & Flavell, R. A. (2001). Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells. Nature Medicine, 7(10), 1118–1122.
Grada, Z., Hegde, M., et al. (2013). TanCAR: A novel bispecific chimeric antigen receptor for cancer immunotherapy. Molecular Therapy: Nucleic Acids, 2(7), e105.
Grimm, E. A., Mazumder, A., et al. (1982). Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. The Journal of Experimental Medicine, 155(6), 1823–1841.
Gross, G., Waks, T., et al. (1989). Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proceedings of the National Academy of Sciences of the United States of America, 86(24), 10024–10028.
Grupp, S. A., Kalos, M., et al. (2013). Chimeric antigen receptor–modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509–1518.
Guha, P., Morgan, J. W., et al. (2013). Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell, 12(4), 407–412.
Haabeth, O. A., Lorvik, K. B., et al. (2011). Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nature Communications, 2, 240.
Hadrup, S. R., Bakker, A. H., et al. (2009). Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nature Methods, 6(7), 520–526.
Halapi, E., Yamamoto, Y., et al. (1993). Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas. Cancer Immunology, Immunotherapy, 36(3), 191–197.
Hami, L. S., Green, C., et al. (2004). GMP production and testing of Xcellerated T cells for the treatment of patients with CLL. Cytotherapy, 6(6), 554–562.
Hamid, O., Robert, C., et al. (2013). Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma. New England Journal of Medicine, 369(2), 134–144.
Han, S., Zhang, C., et al. (2014). Tumour-infiltrating CD4(+) and CD8(+) lymphocytes as predictors of clinical outcome in glioma. British Journal of Cancer, 110(10), 2560–2568.
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
Hao, J., Dong, S., et al. (2011). Regulatory role of Vgamma1 gammadelta T cells in tumor immunity through IL-4 production. Journal of Immunology, 187(10), 4979–4986.
Hart, D., Xue, S., et al. (2008). Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. Gene Therapy, 15(8), 625–631.
Hayashi, K., Yonamine, K., et al. (1999). Clonal expansion of T cells that are specific for autologous ovarian tumor among tumor-infiltrating T cells in humans. Gynecologic Oncology, 74(1), 86–92.
Haynes, N. M., van der Most, R. G., et al. (2008). Immunogenic anti-cancer chemotherapy as an emerging concept. Current Opinion in Immunology, 20(5), 545–557.
Herberman, R. B., Nunn, M. E., et al. (1975). Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity. International Journal of Cancer, 16(2), 216–229.
Hinrichs, C. S., Borman, Z. A., et al. (2009). Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 106(41), 17469–17474.
Hodi, F. S., O’Day, S. J., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8), 711–723.
Hogquist, K. A., Baldwin, T. A., et al. (2005). Central tolerance: Learning self-control in the thymus. Nature Reviews Immunology, 5(10), 772–782.
Holmes, E. C. (1985). Immunology of tumor infiltrating lymphocytes. Annals of Surgery, 201(2), 158.
Hombach, A. A., & Abken, H. (2011). Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. International Journal of Cancer, 129(12), 2935–2944.
Hombach, A. A., Heiders, J., et al. (2012). OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology, 1(4), 458–466.
Hongeng, S., Petvises, S., et al. (2003). Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. International Journal of Hematology, 77(2), 175–179.
Huang, J., Khong, H. T., et al. (2005). Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. Journal of Immunotherapy, 28(3), 258–267.
Hudecek, M., Lupo-Stanghellini, M. T., et al. (2013). Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clinical Cancer Research, 19(12), 3153–3164.
Hui, D., Qiang, L., et al. (2009). A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Digestive and Liver Disease, 41(1), 36–41.
Hwang, W. T., Adams, S. F., et al. (2012). Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecologic Oncology, 124(2), 192–198.
Ismail-Zade, R. S., Zhavrid, E. A., et al. (2010). Use of LAK-cells and systemic chemotherapy with hyperthermia in the management of chemo-resistant tumors. Voprosy Onkologii, 56(6), 681–686.
Itzhaki, O., Hovav, E., et al. (2011). Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy. Journal of Immunotherapy, 34(2), 212–220.
Jain, R. K. (2013). Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. Journal of Clinical Oncology, 31(17), 2205–2218.
Janssen, E. M., Lemmens, E. E., et al. (2003). CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature, 421(6925), 852–856.
Jiang, G., Yang, H. R., et al. (2008). Hepatic stellate cells preferentially expand allogeneic CD4+ CD25+ FoxP3+ regulatory T cells in an IL-2-dependent manner. Transplantation, 86(11), 1492–1502.
Jiang, H., Zhang, W., et al. (2014). Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. Molecular Oncology, 8(2), 297–310.
John, L. B., Devaud, C., et al. (2013). Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clinical Cancer Research, 19(20), 5636–5646.
Johnson, L. A., Morgan, R. A., et al. (2009). Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 114(3), 535–546.
Jorritsma, A., Gomez-Eerland, R., et al. (2007). Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood, 110(10), 3564–3572.
Junker, N., Andersen, M. H., et al. (2011). Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. Journal of Skin Cancer, 2011, 574695.
Kageyama, S., Ikeda, H., et al. (2015). Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clinical Cancer Research, 21(10), 2268–2277.
Kalaitsidou, M., Kueberuwa, G., et al. (2015). CAR T-cell therapy: Toxicity and the relevance of preclinical models. Immunotherapy, 7(5), 487–497.
Kalos, M., Levine, B. L., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine, 3(95), 95ra73.
Kaneko, S., Mastaglio, S., et al. (2009). IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood, 113(5), 1006–1015.
Kato, M., Goto, S., et al. (2010). Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma. Anticancer Research, 30(8), 3125–3128.
Keilholz, U., Scheibenbogen, C., et al. (1994). Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. European Journal of Cancer, 30A(1), 103–105.
Kershaw, M. H., Teng, M. W., et al. (2005). Supernatural T cells: Genetic modification of T cells for cancer therapy. Nature Reviews Immunology, 5(12), 928–940.
Kershaw, M. H., Westwood, J. A., et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clinical Cancer Research, 12(20), 6106–6115.
Kershaw, M. H., Westwood, J. A., et al. (2014). Clinical application of genetically modified T cells in cancer therapy. Clinical Translational Immunology, 3(5), e16.
Kessler, B., Hudrisier, D., et al. (1998). Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity or cytokine production. Journal of Immunology, 161(12), 6939–6946.
Kiessling, R., Klein, E., et al. (1975). “Natural” killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. European Journal of Immunology, 5(2), 112–117.
Kim, S., Iizuka, K., et al. (2000). In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proceedings of the National Academy of Sciences of the United States of America, 97(6), 2731–2736.
Kim, J. Y., Son, Y. O., et al. (2006). Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Experimental and Molecular Medicine, 38(5), 474–484.
Kimura, H., & Yamaguchi, Y. (1997). A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer, 80(1), 42–49.
Kimura, H., Iizasa, T., et al. (2008). Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Research, 28(2B), 1229–1238.
Klaver, Y., Kunert, A., et al. (2015). Adoptive T-cell therapy: A need for standard immune monitoring. Immunotherapy, 7(5), 513–533.
Kloss, C. C., Condomines, M., et al. (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology, 31(1), 71–75.
Knorr, D. A., & Kaufman, D. S. (2010). Pluripotent stem cell-derived natural killer cells for cancer therapy. Translational Research, 156(3), 147–154.
Knorr, D. A., Ni, Z., et al. (2013). Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. Stem Cells Translation Medicine, 2(4), 274–283.
Kobayashi, H., Tanaka, Y., et al. (2011). A new indicator of favorable prognosis in locally advanced renal cell carcinomas: Gamma delta T-cells in peripheral blood. Anticancer Research, 31(3), 1027–1031.
Kochenderfer, J. N., Dudley, M. E., et al. (2015). Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. Journal of Clinical Oncology, 33(6), 540–549.
Kono, K., Takahashi, A., et al. (2002). Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: A randomized trial. Clinical Cancer Research, 8(6), 1767–1771.
Kowalczyk, D., Skorupski, W., et al. (1997). Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. British Journal of Urology, 80(4), 543–547.
Krause, S. W., Gastpar, R., et al. (2004). Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: A clinical phase i trial. Clinical Cancer Research, 10(11), 3699–3707.
Kuball, J., Dossett, M. L., et al. (2007). Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood, 109(6), 2331–2338.
Kuball, J., Hauptrock, B., et al. (2009). Increasing functional avidity of TCR-redirected T cells by removing defined N-glycosylation sites in the TCR constant domain. Journal of Experimental Medicine, 206(2), 463–475.
Kuhl, A. A., Pawlowski, N. N., et al. (2009). Human peripheral gammadelta T cells possess regulatory potential. Immunology, 128(4), 580–588.
Kunert, A., Straetemans, T., et al. (2013). TCR-engineered T cells meet new challenges to treat solid tumors: Choice of antigen, T cell fitness, and sensitization of tumor milieu. Frontiers in Immunology, 4, 363.
Kvistborg, P., Philips, D., et al. (2014). Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Science Translational Medicine, 6(254), 254ra128.
Labrecque, N., Whitfield, L. S., et al. (2001). How much TCR does a T cell need? Immunity, 15(1), 71–82.
Lacuesta, K., Buza, E., et al. (2006). Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. Journal of Immunotherapy, 29(3), 250–260.
Lamb, L. S., Jr., Musk, P., et al. (2001). Human gammadelta(+) T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic response. Bone Marrow Transplantation, 27(6), 601–606.
Lamers, C. H., Gratama, J. W., et al. (2005). Parallel detection of transduced T lymphocytes after immunogene therapy of renal cell cancer by flow cytometry and real-time polymerase chain reaction: Implications for loss of transgene expression. Human Gene Therapy, 16(12), 1452–1462.
Lamers, C. H., Sleijfer, S., et al. (2006). Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: First clinical experience. Journal of Clinical Oncology, 24(13), e20–e22.
Larkin, J., Chiarion-Sileni, V., et al. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1), 23–34.
Larsson, M., Fonteneau, J. F., et al. (2001). Dendritic cells resurrect antigens from dead cells. Trends in Immunology, 22(3), 141–148.
Laurent, S., Queirolo, P., et al. (2013). The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. Journal of Translational Medicine, 11(108.10), 1186.
Leavy, O. (2010). Therapeutic antibodies: Past, present and future. Nature Reviews Immunology, 10(5), 297–297.
Lee, A. J., Kim, S. G., et al. (2012). gammadelta T cells are increased in the peripheral blood of patients with gastric cancer. Clinica Chimica Acta, 413(19–20), 1495–1499.
Lee, D. W., Kochenderfer, J. N., et al. (2015a). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet, 385(9967), 517–528.
Lee, J. H., Lim, Y. S., et al. (2015b). Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology, 148, 1383.
Leisegang, M., Engels, B., et al. (2008a). Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. Journal of Molecular Medicine, 86(5), 573–583.
Leisegang, M., Engels, B., et al. (2008b). Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. Journal Molecule Medicine (Berlin), 86(5), 573–583.
Lesterhuis, W. J., Haanen, J. B., et al. (2011). Cancer immunotherapy–revisited. Nature Reviews Drug Discovery, 10(8), 591–600.
Leuci, V., Mesiano, G., et al. (2014). Genetically redirected T lymphocytes for adoptive immunotherapy of solid tumors. Current Gene Therapy, 14(1), 52–62.
Li, L.-P., Lampert, J. C., et al. (2010). Transgenic mice with a diverse human T cell antigen receptor repertoire. Nature Medicine, 16(9), 1029–1034.
Li, Y., Meng, F. D., et al. (2014). Impact of IL-2 and IL-2R SNPs on proliferation and tumor- killing activity of lymphokine-activated killer cells from healthy chinese blood donors. Asian Pacific Journal of Cancer Prevention, 15(18), 7965–7970.
Linette, G. P., Stadtmauer, E. A., et al. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 122(6), 863–871.
Lipowska-Bhalla, G., Gilham, D. E., et al. (2012). Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges. Cancer Immunology, Immunotherapy, 61(7), 953–962.
Liu, L., Zhang, W., et al. (2012). Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clinical Cancer Research, 18(6), 1751–1759.
Long, E. O., Kim, H. S., et al. (2013). Controlling natural killer cell responses: Integration of signals for activation and inhibition. Annual Review of Immunology, 31, 227–258.
Loskog, A., Giandomenico, V., et al. (2006). Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia, 20(10), 1819–1828.
Lozupone, F., Pende, D., et al. (2004). Effect of human natural killer and gammadelta T cells on the growth of human autologous melanoma xenografts in SCID mice. Cancer Research, 64(1), 378–385.
Lu, Y. C., Yao, X., et al. (2014). Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clinical Cancer Research, 20(13), 3401–3410.
Lutsiak, M. E., Semnani, R. T., et al. (2005). Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood, 105(7), 2862–2868.
Ma, C., & Armstrong, A. W. (2014). Severe adverse events from the treatment of advanced melanoma: A systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. The Journal of Dermatological Treatment, 25(5), 401–408.
Ma, C., Zhang, Q., et al. (2012). Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer. Journal of Immunology, 189(10), 5029–5036.
Ma, S., Cheng, Q., et al. (2014). IL-17A produced by gammadelta T cells promotes tumor growth in hepatocellular carcinoma. Cancer Research, 74(7), 1969–1982.
Maher, J., Brentjens, R. J., et al. (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nature Biotechnology, 20(1), 70–75.
Mahmoud, S. M., Paish, E. C., et al. (2011). Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. Journal of Clinical Oncology, 29(15), 1949–1955.
Maker, A. V., Phan, G. Q., et al. (2005). Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte–associated antigen 4 blockade and interleukin 2: A phase I/II study. Annals of Surgical Oncology, 12(12), 1005–1016.
Märten, A., Ziske, C., et al. (2001). Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. Journal of Immunotherapy, 24(6), 502–510.
Marx, J. (2008). All in the stroma: Cancer’s Cosa Nostra. Science, 320(5872), 38–41.
Maude, S. L., Frey, N., et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507–1517.
Mazumder, A., & Rosenberg, S. A. (1984). Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. The Journal of Experimental Medicine, 159(2), 495–507.
Melder, R. J., Whiteside, T. L., et al. (1988). A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Research, 48(12), 3461–3469.
Menard, C., Martin, F., et al. (2008). Cancer chemotherapy: Not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunology, Immunotherapy, 57(11), 1579–1587.
Metcalfe, W., Anderson, J., et al. (2015). Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. Discovery Medicine, 19(106), 393–401.
Miller, J. S., Tessmer-Tuck, J., et al. (1997). Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity. Biology of Blood and Marrow Transplantation, 3(1), 34–44.
Milone, M. C., Fish, J. D., et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Molecular Therapy, 17(8), 1453–1464.
Mitchison, N. (1955). Studies on the immunological response to foreign tumor transplants in the mouse I. The role of lymph node cells in conferring immunity by adoptive transfer. The Journal of Experimental Medicine, 102(2), 157–177.
Morgan, R. A., Dudley, M. E., et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314(5796), 126–129.
Morgan, R. A., Chinnasamy, N., et al. (2013). Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. Journal of Immunotherapy, 36(2), 133–151.
Motoyoshi, Y., Kaminoda, K., et al. (2006). Different mechanisms for anti-tumor effects of low- and high-dose cyclophosphamide. Oncology Reports, 16(1), 141–146.
Mule, J. J., Shu, S., et al. (1984). Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science, 225(4669), 1487–1489.
Muller, T., Uherek, C., et al. (2008). Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells. Cancer Immunology, Immunotherapy, 57(3), 411–423.
Muranski, P., Boni, A., et al. (2006). Increased intensity lymphodepletion and adoptive immunotherapy – How far can we go? Nature Clinical Practice Oncology, 3(12), 668–681.
Muul, L. M., Spiess, P. J., et al. (1987). Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. Journal of Immunology, 138(3), 989–995.
Nagaraj, S., Ziske, C., et al. (2004). Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Therapy, 2(1), 12.
Nagorsen, D., Scheibenbogen, C., et al. (2003). Natural T cell immunity against cancer. Clinical Cancer Research, 9(12), 4296–4303.
Ni, Z., Knorr, D. A., et al. (2013). Hematopoietic and nature killer cell development from human pluripotent stem cells. Methods in Molecular Biology, 1029, 33–41.
Nicholson, E., Ghorashian, S., et al. (2012). Improving TCR gene therapy for treatment of haematological malignancies. Advance Hematology, 2012, 404081.
North, R. J. (1982). Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. Journal of Experimental Medicine, 155(4), 1063–1074.
O’Brien, S. G., Guilhot, F., et al. (2003). Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New England Journal of Medicine, 348(11), 994–1004.
Obeid, M., Tesniere, A., et al. (2007). Ecto-calreticulin in immunogenic chemotherapy. Immunology Reviews, 220, 22–34.
Oberoi, P., & Wels, W. S. (2013). Arming NK cells with enhanced antitumor activity: CARs and beyond. Oncoimmunology, 2(8), e25220.
Ochi, T., Fujiwara, H., et al. (2011). Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety. Blood, 118(6), 1495–1503.
Okamoto, S., Mineno, J., et al. (2009). Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR. Cancer Research, 69(23), 9003–9011.
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252–264.
Park, J. R., DiGiusto, D. L., et al. (2007). Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Molecular Therapy, 15(4), 825–833.
Park, T. S., Rosenberg, S. A., et al. (2011). Treating cancer with genetically engineered T cells. Trends in Biotechnology, 29(11), 550–557.
Parkhurst, M. R., Riley, J. P., et al. (2011a). Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clinical Cancer Research, 17(19), 6287–6297.
Parkhurst, M. R., Yang, J. C., et al. (2011b). T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Molecular Therapy, 19(3), 620–626.
Parolaro, D., Patrini, G., et al. (1990). Pertussis toxin inhibits morphine analgesia and prevents opiate dependence. Pharmacology Biochemistry and Behavior, 35(1), 137–141.
Patel, S. S., Wacholtz, M. C., et al. (1989). Analysis of the functional capabilities of CD3+CD4-CD8- and CD3+CD4+CD8+ human T cell clones. Journal of Immunology, 143(4), 1108–1117.
Paulos, C. M., & June, C. H. (2010). Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. Journal of Clinical Investigation, 120(1), 76–80.
Pegram, H. J., Lee, J. C., et al. (2012). Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood, 119(18), 4133–4141.
Peng, G., Wang, H. Y., et al. (2007). Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway. Immunity, 27(2), 334–348.
Peters, C., Oberg, H. H., et al. (2014). Phenotype and regulation of immunosuppressive Vdelta2-expressing gammadelta T cells. Cellular and Molecular Life Sciences, 71(10), 1943–1960.
Phillips, J. H., & Lanier, L. L. (1986). Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. Journal of Experimental Medicine, 164(3), 814–825.
Platten, M., & Offringa, R. (2015). Cancer immunotherapy: Exploiting neoepitopes. Cell Research, 25(8), 887–888.
Polyak, K., Haviv, I., et al. (2009). Co-evolution of tumor cells and their microenvironment. Trends in Genetics, 25(1), 30–38.
Pouw, N., Treffers-Westerlaken, E., et al. (2010). Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunology, Immunotherapy, 59(6), 921–931.
Powell, D. J., Jr., Dudley, M. E., et al. (2005). Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood, 105(1), 241–250.
Provasi, E., Genovese, P., et al. (2012). Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nature Medicine, 18(5), 807–815.
Pulè, M. A., Straathof, K. C., et al. (2005). A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Molecular Therapy, 12(5), 933–941.
Pulido, J., Kottke, T., et al. (2012). Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nature Biotechnology, 30(4), 337–343.
Quezada, S. A., Simpson, T. R., et al. (2010). Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Journal of Experimental Medicine, 207(3), 637–650.
Rabinovich, G. A., Gabrilovich, D., et al. (2007). Immunosuppressive strategies that are mediated by tumor cells. Annual Review of Immunology, 25, 267–296.
Radvanyi, L. G., Bernatchez, C., et al. (2012). Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clinical Cancer Research, 18(24), 6758–6770.
Rahbar, M., Naraghi, Z. S., et al. (2015). Tumor-infiltrating CD8+ lymphocytes effect on clinical outcome of muco-cutaneous melanoma. Indian Journal of Dermatology, 60(2), 212.
Ralainirina, N., Poli, A., et al. (2007). Control of NK cell functions by CD4+CD25+ regulatory T cells. Journal of Leukocyte Biology, 81(1), 144–153.
Rapoport, A. P., Stadtmauer, E. A., et al. (2015). NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine, 21(8), 914–921.
Ribas, A., & Wolchok, J. D. (2013). Combining cancer immunotherapy and targeted therapy. Current Opinion in Immunology, 25(2), 291–296.
Riddell, S. R., Jensen, M. C., et al. (2013). Chimeric antigen receptor modified T cells–clinical translation in stem cell transplantation and beyond. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation, 19(10), S2.
Ritchie, D. S., Neeson, P. J., et al. (2013). Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Molecular Therapy, 21(11), 2122–2129.
Rizvi, N. A., Hellmann, M. D., et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348(6230), 124–128.
Robbins, P. F., Dudley, M. E., et al. (2004). Cutting edge: Persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. Journal of Immunology, 173(12), 7125–7130.
Robbins, P. F., Li, Y. F., et al. (2008). Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. Journal of Immunology, 180(9), 6116–6131.
Robbins, P. F., Morgan, R. A., et al. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology, 29(7), 917–924.
Robbins, P. F., Lu, Y. C., et al. (2013). Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nature Medicine, 19(6), 747–752.
Rosenberg, S. A. (1988). Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. Important Advances Oncology, 217–257.
Rosenberg, S. A. (2014). Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Therapy, 21(2), 45–47.
Rosenberg, S. A., & Dudley, M. E. (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology, 21(2), 233–240.
Rosenberg, S. A., & Restifo, N. P. (2015). Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 348(6230), 62–68.
Rosenberg, S. A., Lotze, M. T., et al. (1985). Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. New England Journal of Medicine, 313(23), 1485–1492.
Rosenberg, S. A., Spiess, P., et al. (1986). A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science, 233(4770), 1318–1321.
Rosenberg, S. A., Packard, B. S., et al. (1988). Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. New England Journal of Medicine, 319(25), 1676–1680.
Rosenberg, S. A., Lotze, M. T., et al. (1993). Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. Journal of the National Cancer Institute, 85(8), 622–632.
Rosenberg, S. A., Yang, J. C., et al. (2011). Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research, 17(13), 4550–4557.
Sadelain, M., Brentjens, R., et al. (2013). The basic principles of chimeric antigen receptor design. Cancer Discovery, 3(4), 388–398.
Sadovnikova, E., Jopling, L. A., et al. (1998). Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. European Journal of Immunology, 28(1), 193–200.
Sahm, C., Schonfeld, K., et al. (2012). Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor. Cancer Immunology, Immunotherapy, 61(9), 1451–1461.
Saito, H., Ando, S., et al. (2014). A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamous cell carcinoma. Anticancer Research, 34(7), 3365–3370.
Sangiolo, D., Martinuzzi, E., et al. (2008). Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: Implications for their infusion across major HLA barriers. International Immunology, 20(7), 841–848.
Sathish, J. G., Sethu, S., et al. (2013). Challenges and approaches for the development of safer immunomodulatory biologics. Nature Reviews Drug Discovery, 12(4), 306–324.
Savas, B., Cole, S. P., et al. (1996). P-glycoprotein-mediated multidrug resistance and lymphokine-activated killer cell susceptibility in ovarian carcinoma. Journal of Clinical Immunology, 16(6), 348–357.
Savas, B., Kerr, P. E., et al. (1998). Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma. Anticancer Research, 18(6A), 4355–4361.
Savas, B., Arslan, G., et al. (1999). Multidrug resistant malignant melanoma with intracranial metastasis responding to immunotherapy. Anticancer Research, 19(5C), 4413–4420.
Savoldo, B., Ramos, C. A., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. The Journal of Clinical Investigation, 121(5), 1822.
Schade, A. E., Schieven, G. L., et al. (2008). Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood, 111(3), 1366–1377.
Schaft, N., Lankiewicz, B., et al. (2006). T cell re-targeting to EBV antigens following TCR gene transfer: CD28-containing receptors mediate enhanced antigen-specific IFNgamma production. International Immunology, 18(4), 591–601.
Schmid, D. A., Irving, M. B., et al. (2010). Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. Journal of Immunology, 184(9), 4936–4946.
Schmidt, J., Eisold, S., et al. (2004). Dendritic cells reduce number and function of CD4+ CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunology, Immunotherapy, 53(11), 1018–1026.
Schmidt-Wolf, I., Negrin, R. S., et al. (1991). Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. The Journal of Experimental Medicine, 174(1), 139–149.
Schmidt-Wolf, I., Lefterova, P., et al. (1993). Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Experimental Hematology, 21(13), 1673–1679.
Schmidt-Wolf, I., Finke, S., et al. (1999). Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer, 81(6), 1009.
Scholten, K. B., Kramer, D., et al. (2006). Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clinical Immunology, 119(2), 135–145.
Schreiber, R. D., Old, L. J., et al. (2011). Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024), 1565–1570.
Schumacher, T. N., & Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69–74.
Semino, C., Martini, L., et al. (1998). Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience. Anticancer Research, 19(6C), 5645–5649.
Seung, S. K., Curti, B. D., et al. (2012). Phase 1 study of stereotactic body radiotherapy and interleukin-2 – Tumor and immunological responses. Science Translational Medicine, 4(137), 137ra174.
Sharma, P., & Allison, J. P. (2015). Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell, 161(2), 205–214.
Sharpe, M., & Mount, N. (2015). Genetically modified T cells in cancer therapy: Opportunities and challenges. Disease Models & Mechanisms, 8(4), 337–350.
Shen, X., Zhou, J., et al. (2007). Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. Journal of Immunotherapy, 30(1), 123–129.
Sherry, R. M., Rosenberg, S. A., et al. (1991). Relapse after response to interleukin-2-based immunotherapy: Patterns of progression and response to retreatment. Journal Immunotherapy, 10(5), 371–375.
Shi, G., Zhou, C., et al. (2014). Antitumor enhancement by adoptive transfer of tumor antigen primed, inactivated MHC-haploidentical lymphocytes. Cancer Letters, 343(1), 42–50.
Shirasu, N., Shibaguci, H., et al. (2010). Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Anticancer Research, 30(7), 2731–2738.
Shurin, G. V., Tourkova, I. L., et al. (2009). Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. Journal of Immunology, 183(1), 137–144.
Skoberne, M., Beignon, A. S., et al. (2004). Danger signals: A time and space continuum. Trends in Molecular Medicine, 10(6), 251–257.
Snyder, A., Makarov, V., et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. New England Journal of Medicine, 371(23), 2189–2199.
Somerville, R. P., & Dudley, M. E. (2012). Bioreactors get personal. Oncoimmunology, 1(8), 1435–1437.
Song, D.-G., Ye, Q., et al. (2011). In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Research, 71(13), 4617–4627.
Stauss, H. J., & Morris, E. C. (2013). Immunotherapy with gene-modified T cells: Limiting side effects provides new challenges. Gene Therapy, 20(11), 1029–1032.
Suck, G., Oei, V. Y., et al. (2011). Interleukin-15 supports generation of highly potent clinical-grade natural killer cells in long-term cultures for targeting hematological malignancies. Experimental Hematology, 39(9), 904–914.
Taieb, J., Chaput, N., et al. (2006). Chemoimmunotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. Journal of Immunology, 176(5), 2722–2729.
Tamada, K., Geng, D., et al. (2012). Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clinical Cancer Research, 18(23), 6436–6445.
Tanaka, T., Bai, Z., et al. (2005). Chemokines in tumor progression and metastasis. Cancer Science, 96(6), 317–322.
Tarek, N., Le Luduec, J. B., et al. (2012). Unlicensed NK cells target neuroblastoma following anti-GD2 antibody treatment. Journal of Clinical Investigation, 122(9), 3260–3270.
Tartour, E., Pere, H., et al. (2011). Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Reviews, 30(1), 83–95.
Tesniere, A., Apetoh, L., et al. (2008). Immunogenic cancer cell death: A key-lock paradigm. Current Opinion in Immunology, 20(5), 504–511.
Tey, S. K. (2014). Adoptive T-cell therapy: Adverse events and safety switches. Clinical Translation Immunology, 3(6), e17.
Thomas, S., Xue, S. A., et al. (2011). Human T cells expressing affinity-matured TCR display accelerated responses but fail to recognize low density of MHC-peptide antigen. Blood, 118(2), 319–329.
Thomas, S., Klobuch, S., et al. (2012). Strong and sustained effector function of memory- versus naive-derived T cells upon T-cell receptor RNA transfer: Implications for cellular therapy. European Journal of Immunology, 42(12), 3442–3453.
Till, B. G., Jensen, M. C., et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood, 112(6), 2261–2271.
Till, B. G., Jensen, M. C., et al. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: Pilot clinical trial results. Blood, 119(17), 3940–3950.
Toda, A., & Piccirillo, C. A. (2006). Development and function of naturally occurring CD4+CD25+ regulatory T cells. Journal of Leukocyte Biology, 80(3), 458–470.
Tonn, T., Schwabe, D., et al. (2013). Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy, 15(12), 1563–1570.
Topalian, S. L., Hodi, F. S., et al. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England Journal of Medicine, 366(26), 2443–2454.
Tran, K. Q., Zhou, J., et al. (2008). Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. Journal of Immunotherapy, 31(8), 742–751.
Tran, E., Turcotte, S., et al. (2014). Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science, 344(6184), 641–645.
Trapani, J. A., Davis, J., et al. (2000). Proapoptotic functions of cytotoxic lymphocyte granule constituents in vitro and in vivo. Current Opinion in Immunology, 12(3), 323–329.
Traxlmayr, M. W., Wesch, D., et al. (2010). Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells. Journal of Immunotherapy, 33(1), 40–52.
Tseng, J., Citrin, D. E., et al. (2014). Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer, 120(9), 1426–1432.
Urbanska, K., Lanitis, E., et al. (2012). A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Research, 72(7), 1844–1852.
Uyttenhove, C., Pilotte, L., et al. (2003). Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nature Medicine, 9(10), 1269–1274.
Valitutti, S., Muller, S., et al. (1995). Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature, 375(6527), 148–151.
Valitutti, S., Muller, S., et al. (1997). Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. Journal of Experimental Medicine, 185(10), 1859–1864.
Valteau-Couanet, D., Leboulaire, C., et al. (2002). Dendritic cells for NK/LAK activation: Rationale for multicellular immunotherapy in neuroblastoma patients. Blood, 100(7), 2554–2561.
van den Berg, J. H., Gomez-Eerland, R., et al. (2015). Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor. Molecular Therapy, 23, 1541.
Vanneman, M., & Dranoff, G. (2012). Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 12(4), 237–251.
Verdegaal, E. M., Visser, M., et al. (2011). Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha. Cancer Immunology, Immunotherapy, 60(7), 953–963.
Verneris, M. R., Kornacker, M., et al. (2000). Resistance of ex vivo expanded CD3+ CD56+ T cells to Fas-mediated apoptosis. Cancer Immunology, Immunotherapy, 49(6), 335–345.
Vershinina, M., Khalturina, E. O., et al. (2004). Characterization of lymphokine-activated killer cells obtained from the natural killers – T cells of patients with hepatic tumor lesion. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk (12), 32–36.
Vesely, M. D., Kershaw, M. H., et al. (2011). Natural innate and adaptive immunity to cancer. Annual Review of Immunology, 29, 235–271.
Viey, E., Lucas, C., et al. (2008). Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vgamma9Vdelta2 T cells from renal cell carcinoma patients. Journal of Immunotherapy, 31(3), 313–323.
Vivier, E., Tomasello, E., et al. (2008). Functions of natural killer cells. Nature Immunology, 9(5), 503–510.
Vivier, E., Raulet, D. H., et al. (2011). Innate or adaptive immunity? The example of natural killer cells. Science, 331(6013), 44–49.
Vonderheide, R. H., Bajor, D. L., et al. (2013). CD40 immunotherapy for pancreatic cancer. Cancer Immunology, Immunotherapy, 62(5), 949–954.
Vukmanovic-Stejic, M., Zhang, Y., et al. (2006). Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. Journal of Clinical Investigation, 116(9), 2423–2433.
Wang, Q. J., Wang, H., et al. (2010). Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chinese Journal of Cancer, 29(7), 641–648.
Wang, X., Lei, Y., et al. (2013). PD‐1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication. Journal of Viral Hepatitis, 20(s1), 27–39.
Weber, E., Anderson, W. F., et al. (2001). Recent advances in retrovirus vector-mediated gene therapy: Teaching an old vector new tricks. Current Opinion in Molecular Therapeutics, 3(5), 439–453.
Weng, D. S., Zhou, J., et al. (2008). Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. Journal of Immunotherapy, 31(1), 63–71.
West, E. J., Scott, K. J., et al. (2011). Immune activation by combination human lymphokine-activated killer and dendritic cell therapy. British Journal of Cancer, 105(6), 787–795.
Wherry, E. J. (2011). T cell exhaustion. Nature Immunology, 12(6), 492–499.
Whitson, B. A., D’Cunha, J., et al. (2007). Minimally invasive cancer surgery improves patient survival rates through less perioperative immunosuppression. Medical Hypotheses, 68(6), 1328–1332.
Wick, D. A., Webb, J. R., et al. (2014). Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clinical Cancer Research, 20(5), 1125–1134.
Wistuba-Hamprecht, K., Di Benedetto, S. et al. (2015). Phenotypic characterization and prognostic impact of circulating gammadelta and alphabeta T-cells in metastatic malignant melanoma. International Journal Cancer, 138(3), 698–704.
Wolchok, J. D., & Chan, T. A. (2014). Cancer: Antitumour immunity gets a boost. Nature, 515(7528), 496–498.
Wrobel, P., Shojaei, H., et al. (2007). Lysis of a broad range of epithelial tumour cells by human gamma delta T cells: Involvement of NKG2D ligands and T-cell receptor- versus NKG2D-dependent recognition. Scandinavian Journal of Immunology, 66(2–3), 320–328.
Wrzesinski, C., & Restifo, N. P. (2005). Less is more: Lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Current Opinion in Immunology, 17(2), 195–201.
Wrzesinski, C., Paulos, C. M., et al. (2010). Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. Journal of Immunotherapy (Hagerstown, Md.: 1997), 33(1), 1.
Wu, C., Jiang, J., et al. (2008). Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Research, 28(6B), 3997–4002.
Wu, P., Wu, D., et al. (2014). gammadeltaT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. Immunity, 40(5), 785–800.
Wu, D., Wu, P., et al. (2015). Expanded human circulating Vdelta1 gammadeltaT cells exhibit favorable therapeutic potential for colon cancer. Oncoimmunology, 4(3), e992749.
Yamaguchi, Y., Hihara, J., et al. (2006). Postoperative immunosuppression cascade and immunotherapy using lymphokine-activated killer cells for patients with esophageal cancer: Possible application for compensatory anti-inflammatory response syndrome. Oncology Reports, 15(4), 895–901.
Yamamoto, Y., Backlin, K., et al. (1993). Cytotoxic activity and T cell receptor repertoire in tumor-infiltrating lymphocytes of adrenal cell carcinomas. Cancer Immunology, Immunotherapy, 37(3), 163–168.
Yang, L., Ren, B., et al. (2013). Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunology, Immunotherapy, 62(1), 65–73.
Young, J. D., Liu, C. C., et al. (1988). Molecular mechanisms of lymphocyte-mediated killing. Brazilian Journal of Medical and Biological Research, 21(6), 1145–1153.
Zhang, Q., Yang, X., et al. (2005). Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: Eradication of autologous mouse prostate cancer. Cancer Research, 65(5), 1761–1769.
Zhang, B., Bowerman, N. A., et al. (2007). Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. The Journal of Experimental Medicine, 204(1), 49–55.
Zhao, Y., Zheng, Z., et al. (2006). High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Molecular Therapy, 13(1), 151–159.
Zhao, H., Fan, Y., et al. (2013). Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: A retrospective study of 165 patients. Cancer Biotherapy and Radiopharmaceuticals, 28(4), 303–309.
Zhao, Y. J., Jiang, N., et al. (2015). Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments. Asian Pacific Journal of Cancer Prevention, 16(6), 2419–2423.
Zheng, W., & Flavell, R. A. (1997). The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell, 89(4), 587–596.
Zheng, B. J., Chan, K. W., et al. (2001). Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. International Journal of Cancer, 92(3), 421–425.
Zhong, X.-S., Matsushita, M., et al. (2010). Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell–mediated tumor eradication. Molecular Therapy, 18(2), 413–420.
Zhou, J., Shen, X., et al. (2005). Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. Journal of Immunology, 175(10), 7046–7052.
Zhou, Q., Gil-Krzewska, A., et al. (2013). Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy. Clinical and Experimental Immunology, 173(1), 131–139.
Zitvogel, L., & Kroemer, G. (2011). Anticancer effects of imatinib via immunostimulation. Nature Medicine, 17(9), 1050–1051.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Yang, F. et al. (2016). Adoptive Cellular Therapy (ACT) for Cancer Treatment. In: Zhang, S. (eds) Progress in Cancer Immunotherapy. Advances in Experimental Medicine and Biology, vol 909. Springer, Dordrecht. https://doi.org/10.1007/978-94-017-7555-7_4
Download citation
DOI: https://doi.org/10.1007/978-94-017-7555-7_4
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-017-7553-3
Online ISBN: 978-94-017-7555-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)